wondering whether a different combo trial could be run in R/R AML so pricing isn’t eroded.
I don’t know much about how the price is determined, so based on the triangle report favouring a cardio protect + anti cancer effect.
thinking outside the box, to achieve this could Race do a 3 in 1 combo trial. Here is my thoughts:
R/R AML 3-in-1 #Decatabine + Venetoclax + Bisantrene
Bisantrene synergises with Decitabine
Bisantrene synergises with Venetoclax
Decitabine promotes FTO expression
Venetoclax is cardiotoxic
R/R AML overexpresses FTO
This supports Cardio protect, anti cancer and FTO all in one. Anything I’m missing why this would not work be a good idea scientifically or commercially?
How long would it take to check the combo invitro for synergy and cardio protect?
wondering whether a different combo trial could be run in R/R...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26825 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 759 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |